Howard Chertkow

Dr. Howard Chertkow-Cognitive Neurologist- June 2018
Senior Scientist and Chair in Cognitive Neurology and Innovation, Rotman Research Institute, Baycrest Health Sciences (from August, 2018).
Director, Kimel Central for Brain Health and Baycrest Clinical Trials Unit;
Professor of Neurology, Division of Neurology, Dept. of Medicine, University of Toronto, Scientific Director, Canadian Consortium on Neurodegeneration in Aging.
Affiliate Member, Dept. of Neurology, McGill University and Lady Davis Institute for Medicial Research, Jewish General Hospital.

Dr. Howard Chertkow is currently a practicing cognitive neurologist at Baycrest Health Sciences at University of Toronto, where he participates in the memory clinic, directs clinical trials in the Clinical Trials Unit, directs the Kimel Centre for Brain Health, and runs a laboratory focussed on tDCS therapy for dementia. He sees patients with Alzheimer Disease and other dementias in their early stages, for diagnosis and treatment.
Dr. Chertkow is an active researcher in the area of dementia. Dr. Chertkow’s major areas of research interest include 1) Early diagnosis of Alzheimer’s Disease and prediction of deterioration in individuals with Mild Cognitive Impairment, 2) the structure, organization, and function of the Semantic Memory component of long term memory, and its deterioration in dementia, 3) localization of language and memory functions in the brain using functional imaging, and 4) therapy of cognitive disorders in Alzheimer Disease and Frontotemporal dementia using neuromodulation approaches. His CV lists 270 publications, including 170 peer-reviewed articles and chapters. Thirty-two of his publications have over 100 citations, and three of the publications have been cited over 1000 times.
In 2005 he and his colleagues, Ziad Nasreddine and Natalie Phillips, published the Montreal Cognitive Assessment (MoCA), which has become an international standard for diagnosis of MCI, and has been cited over 6,500 times. The MoCA is now used around the world to screen for cognitive loss in the elderly. Thompson Reuters’ Essential Science Indicators noted this to be the most cited paper in mild cognitive impairment, 2006-2009, and it is the most cited paper in the field of neurology in the world in the 21st century.Dr. Chertkow is Scientific Director of the national dementia research group - CCNA. .

Additional information

Chair in Cognitive Neurology and Innovation